Matthew Sykes
Stock Analyst at Goldman Sachs
(4.09)
# 539
Out of 5,116 analysts
210
Total ratings
55.1%
Success rate
11.15%
Average return
Main Sectors:
Stocks Rated by Matthew Sykes
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| FTRE Fortrea Holdings | Maintains: Neutral | $7 → $5 | $17.40 | -71.26% | 4 | May 14, 2025 | |
| CTKB Cytek Biosciences | Maintains: Sell | $3.5 → $3 | $5.10 | -41.18% | 14 | May 12, 2025 | |
| TXG 10x Genomics | Maintains: Sell | $7.5 → $6.5 | $16.49 | -60.58% | 7 | May 12, 2025 | |
| BRKR Bruker | Maintains: Neutral | $50 → $45 | $48.01 | -6.27% | 5 | May 8, 2025 | |
| MYGN Myriad Genetics | Maintains: Buy | $14 → $8 | $6.48 | +23.46% | 12 | May 7, 2025 | |
| TWST Twist Bioscience | Maintains: Buy | $55 → $48 | $33.05 | +45.23% | 10 | May 6, 2025 | |
| SHC Sotera Health Company | Upgrades: Buy | $14 → $17 | $17.70 | -3.95% | 1 | May 5, 2025 | |
| ICLR ICON Public Limited Company | Maintains: Neutral | $180 → $160 | $182.84 | -12.49% | 4 | May 2, 2025 | |
| NEO NeoGenomics | Maintains: Buy | $15 → $10 | $12.28 | -18.57% | 8 | Apr 30, 2025 | |
| RVTY Revvity | Maintains: Buy | $140 → $125 | $96.75 | +29.20% | 2 | Apr 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $23 → $14 | $11.43 | +22.48% | 6 | Apr 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $260 → $240 | $230.32 | +4.20% | 5 | Apr 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $34 → $26 | $19.48 | +33.47% | 10 | Apr 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $190 → $170 | $203.66 | -16.53% | 4 | Mar 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $49 → $56 | $102.98 | -45.62% | 13 | Feb 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $70 → $80 | $133.79 | -40.20% | 11 | Feb 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $1.75 → $1.5 | $1.77 | -15.25% | 5 | Feb 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $160 → $190 | $233.74 | -18.71% | 13 | Jan 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $2.25 → $1.75 | $1.98 | -11.62% | 5 | Dec 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $7 → $4.25 | $3.26 | +30.37% | 10 | Dec 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $38 → $37 | $42.49 | -12.92% | 5 | Dec 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $75 → $65 | $101.57 | -36.00% | 13 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $280 → $250 | $226.92 | +10.17% | 2 | Nov 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $35 → $24 | $6.46 | +271.52% | 13 | Jul 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $1,150 → $1,300 | $1,420.10 | -8.46% | 7 | Jul 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $32 → $12 | $8.40 | +42.86% | 6 | Jul 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $550 → $640 | $580.74 | +10.20% | 6 | Apr 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $128 → $145 | $138.39 | +4.78% | 4 | Dec 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $45.37 | - | 5 | Dec 7, 2023 |
Fortrea Holdings
May 14, 2025
Maintains: Neutral
Price Target: $7 → $5
Current: $17.40
Upside: -71.26%
Cytek Biosciences
May 12, 2025
Maintains: Sell
Price Target: $3.5 → $3
Current: $5.10
Upside: -41.18%
10x Genomics
May 12, 2025
Maintains: Sell
Price Target: $7.5 → $6.5
Current: $16.49
Upside: -60.58%
Bruker
May 8, 2025
Maintains: Neutral
Price Target: $50 → $45
Current: $48.01
Upside: -6.27%
Myriad Genetics
May 7, 2025
Maintains: Buy
Price Target: $14 → $8
Current: $6.48
Upside: +23.46%
Twist Bioscience
May 6, 2025
Maintains: Buy
Price Target: $55 → $48
Current: $33.05
Upside: +45.23%
Sotera Health Company
May 5, 2025
Upgrades: Buy
Price Target: $14 → $17
Current: $17.70
Upside: -3.95%
ICON Public Limited Company
May 2, 2025
Maintains: Neutral
Price Target: $180 → $160
Current: $182.84
Upside: -12.49%
NeoGenomics
Apr 30, 2025
Maintains: Buy
Price Target: $15 → $10
Current: $12.28
Upside: -18.57%
Revvity
Apr 29, 2025
Maintains: Buy
Price Target: $140 → $125
Current: $96.75
Upside: +29.20%
Apr 29, 2025
Downgrades: Neutral
Price Target: $23 → $14
Current: $11.43
Upside: +22.48%
Apr 23, 2025
Maintains: Buy
Price Target: $260 → $240
Current: $230.32
Upside: +4.20%
Apr 17, 2025
Maintains: Buy
Price Target: $34 → $26
Current: $19.48
Upside: +33.47%
Mar 21, 2025
Downgrades: Neutral
Price Target: $190 → $170
Current: $203.66
Upside: -16.53%
Feb 21, 2025
Maintains: Buy
Price Target: $49 → $56
Current: $102.98
Upside: -45.62%
Feb 19, 2025
Maintains: Neutral
Price Target: $70 → $80
Current: $133.79
Upside: -40.20%
Feb 18, 2025
Maintains: Neutral
Price Target: $1.75 → $1.5
Current: $1.77
Upside: -15.25%
Jan 28, 2025
Maintains: Buy
Price Target: $160 → $190
Current: $233.74
Upside: -18.71%
Dec 5, 2024
Downgrades: Sell
Price Target: $2.25 → $1.75
Current: $1.98
Upside: -11.62%
Dec 5, 2024
Downgrades: Sell
Price Target: $7 → $4.25
Current: $3.26
Upside: +30.37%
Dec 5, 2024
Downgrades: Neutral
Price Target: $38 → $37
Current: $42.49
Upside: -12.92%
Nov 6, 2024
Maintains: Buy
Price Target: $75 → $65
Current: $101.57
Upside: -36.00%
Nov 1, 2024
Maintains: Buy
Price Target: $280 → $250
Current: $226.92
Upside: +10.17%
Jul 9, 2024
Maintains: Buy
Price Target: $35 → $24
Current: $6.46
Upside: +271.52%
Jul 9, 2024
Maintains: Neutral
Price Target: $1,150 → $1,300
Current: $1,420.10
Upside: -8.46%
Jul 9, 2024
Maintains: Sell
Price Target: $32 → $12
Current: $8.40
Upside: +42.86%
Apr 10, 2024
Maintains: Buy
Price Target: $550 → $640
Current: $580.74
Upside: +10.20%
Dec 7, 2023
Maintains: Buy
Price Target: $128 → $145
Current: $138.39
Upside: +4.78%
Dec 7, 2023
Upgrades: Buy
Price Target: n/a
Current: $45.37
Upside: -